What Happened?
South San Francisco, -based Portola Resigned Michael Ouimette as Executive Director and Assistant Corporate Secretary
About the Company
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
About the Person
Michael Ouimette is General Counsel and Corporate Secretary at Pliant Therapeutics. Previously, Michael held various senior legal leadership roles in the industry.
Info Source
News
Short Profile